ArticleBMC immunology2021

Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501).

Fabien Francois et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.